IRF2BP2 counteracts the ATF7/JDP2 AP-1 heterodimer to prevent inflammatory overactivation in acute myeloid leukemia (AML) cells

Sabrina Fischer,Lisa Marie Weber,Bastian Stielow,Miriam Frech,Clara Simon,Merle Geller,Julie Könnecke,Florian Finkernagel,Ignasi Forné,Andrea Nist,Uta-Maria Bauer,Thorsten Stiewe,Andreas Neubauer,Robert Liefke

DOI: https://doi.org/10.1093/nar/gkae437

IF: 14.9

2024-05-29

Nucleic Acids Research

Abstract:Acute myeloid leukemia (AML) is a hematological malignancy characterized by abnormal proliferation and accumulation of immature myeloid cells in the bone marrow. Inflammation plays a crucial role in AML progression, but excessive activation of cell-intrinsic inflammatory pathways can also trigger cell death. IRF2BP2 is a chromatin regulator implicated in AML pathogenesis, although its precise role in this disease is not fully understood. In this study, we demonstrate that IRF2BP2 interacts with the AP-1 heterodimer ATF7/JDP2, which is involved in activating inflammatory pathways in AML cells. We show that IRF2BP2 is recruited by the ATF7/JDP2 dimer to chromatin and counteracts its gene-activating function. Loss of IRF2BP2 leads to overactivation of inflammatory pathways, resulting in strongly reduced proliferation. Our research indicates that a precise equilibrium between activating and repressive transcriptional mechanisms creates a pro-oncogenic inflammatory environment in AML cells. The ATF7/JDP2-IRF2BP2 regulatory axis is likely a key regulator of this process and may, therefore, represent a promising therapeutic vulnerability for AML. Thus, our study provides new insights into the molecular mechanisms underlying AML pathogenesis and identifies a potential therapeutic target for AML treatment.

biochemistry & molecular biology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is the problem of cell death caused by excessive activation of inflammation in acute myeloid leukemia (AML). Specifically, the study focused on how IRF2BP2 interacts with the AP - 1 heterodimer (composed of ATF7 and JDP2) to inhibit the over - expression of inflammatory genes, thereby preventing excessive activation of inflammation in AML cells. The deletion of IRF2BP2 will lead to excessive activation of the inflammatory pathway, which in turn inhibits cell proliferation and ultimately leads to cell death. Therefore, the study aims to explore the specific mechanism of action of IRF2BP2 in AML and its potential as a therapeutic target.

### Research Background
Acute myeloid leukemia (AML) is a hematological malignancy characterized by abnormal proliferation and accumulation of immature myeloid cells in the bone marrow. Inflammation plays a crucial role in the progression of AML, but excessive activation of the intracellular inflammatory pathway may also trigger cell death. IRF2BP2 is a chromatin regulator that plays a role in the pathogenesis of AML, but its specific role is not fully understood.

### Research Objectives
1. **Reveal the specific function of IRF2BP2**: Study how IRF2BP2 interacts with the AP - 1 heterodimer (ATF7/JDP2) to regulate the expression of inflammatory genes.
2. **Explore the mechanism of action of IRF2BP2 in AML**: Analyze the impact of the deletion of IRF2BP2 on the proliferation and survival of AML cells.
3. **Evaluate the potential of IRF2BP2 as a therapeutic target**: Study the possibility of controlling inflammation and promoting leukemia cell death by regulating the IRF2BP2 - AP - 1 axis.

### Main Findings
- **Interaction between IRF2BP2 and AP - 1 heterodimer**: IRF2BP2 interacts with the AP - 1 heterodimer (ATF7/JDP2) and is recruited to chromatin.
- **IRF2BP2 inhibits the expression of inflammatory genes**: IRF2BP2 prevents the over - expression of inflammatory genes by inhibiting the gene - activation function of the AP - 1 heterodimer.
- **Excessive activation of inflammation due to IRF2BP2 deletion**: The deletion of IRF2BP2 leads to excessive activation of the inflammatory pathway, inhibits cell proliferation and ultimately leads to cell death.
- **Potential therapeutic target**: The research results indicate that treatment strategies targeting the IRF2BP2 - AP - 1 axis may help control the inflammatory response in AML and promote the death of leukemia cells.

### Conclusion
This study provides new insights into the pathogenesis of AML, especially the important role of IRF2BP2 in regulating the expression of inflammatory genes. These findings provide potential targets for the development of new AML treatment methods.